Apic: Dual-gene therapies

How Apic is developing a dual function gene therapy for AAT deficiency

Apic Bio Inc.'s APB-101 is a dual-function gene therapy for AAT deficiency that silences the mutant AAT gene and augments wild-type AAT expression, which the company believes gives it greater efficacy and lower liver toxicity than other gene silencing or gene replacement therapies for the disease.

Apic's John Reilly and Christian Mueller said APB-101, which was designed using Apic's THRIVE platform, differs

Read the full 613 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE